1. COVID-19 Vaccination in Liver Cirrhosis: Safety and Immune and Clinical Responses
- Author
-
Inês Canha, Mário Jorge Silva, Maria Azevedo Silva, Mara Sarmento Costa, Rita Ornelas Saraiva, André Ruge, Mariana Verdelho Machado, Catarina Sousa Félix, Bárbara Morão, Pedro Narra Figueiredo, Milena Mendes, Carina Leal, and Filipe Calinas
- Subjects
covid-19 ,liver cirrhosis ,vaccine ,infection ,antibodies ,cirrose hepática ,vacina ,infeção ,anticorpos ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Introduction: Three years after the beginning of the SARS-CoV-2 pandemic, the safety and efficacy of COVID-19 vaccination in liver cirrhosis (LC) patients remain controversial. We aimed to study the safety, immunological, and clinical responses of LC patients to COVID-19 vaccination. Methods: Prospective multicentric study in adults with LC eligible for COVID-19 vaccination, without prior known infection. Patients were followed up until the timing of a booster dose, SARS-CoV-2 infection, or death. Spike-protein immunoglobulin G antibody titers for SARS-CoV-2 at 2 weeks, 3 months, and 6 months postvaccination were assessed. Antibody titers 200 BAU/mL at 3 months. Conclusion: COVID-19 vaccines in patients with LC were safe, without serious adverse events. The humoral and clinical responses were similar to the reported for the general population. Humoral response was adversely impacted by older age and adenovirus vector vaccines and unrelated to the liver disease severity.
- Published
- 2023
- Full Text
- View/download PDF